- 4009 Hackney Springs Ln, Sachse, TX 75048
Transplant continuum billing spans four distinct reimbursement systems: molecular rejection surveillance on a payer-defined calendar, immunosuppressant levels billed by trough timing, tissue allografts through HCPCS Q-codes with FDA requirements, and pre-transplant testing sometimes routed through the organ acquisition cost center. Generalist billers rarely track all four; loss compounds quietly until an audit reveals it.
dd-cfDNA Monitoring Frequency Miscoding
Gene Expression Profiling & dd-cfDNA Combined Billing Errors
Tissue Bank Q-Code Eligibility Gaps
Immunosuppressant Panel Bundling & Timing Errors
Post-Transplant Viral Surveillance Timing Denials
From molecular rejection surveillance to tissue bank allograft billing, our AAPC/AHIMA-certified coders know the CPT, PLA, and HCPCS rules, payer-specific monitoring calendars, and regulatory requirements across the full post-transplant continuum.
TransLabs’ specialized RCM services are built exclusively for labs, addressing the unique challenges that generalist billers miss. We provide end-to-end revenue cycle solutions designed specifically to turn laboratory complexity into profitability.
Complete payer enrollment, CLIA certification management, and network participation setup across all insurance carriers. TransLabs manages every credentialing detail so that your laboratory gets paid in-network from day one without any administrative delays.
Real-time insurance verification, benefits investigation, and prior auth completed before specimen processing begins. Confirming coverage upfront eliminates preventable denials and protects your lab from unexpected reimbursement failures.
Patient registration, appointment coordination, insurance verification, and customer service excellence managed by experienced laboratory billing professionals. A well-run front office reduces downstream billing errors and creates a better experience.
TransLabs provides expert RCM services to clinical laboratories in all 50 states, delivering the same exceptional results whether you’re a community hospital lab or a large reference facility. We bring specialized lab billing expertise to facilities nationwide, combining remote efficiency with hands-on partnership.
Coverage for donor-derived cell-free DNA and gene expression profiling testing follows a defined post-transplant monitoring calendar, monthly in the first year, then quarterly, then twice yearly for heart transplant recipients, with similar structured intervals for kidney transplant. TransLabs tracks each patient's post-transplant timeline and validates every claim against the applicable calendar before submission.
Certain pre-transplant testing performed during living or deceased donor evaluation is captured through the transplant hospital's organ acquisition cost center rather than billed as a standalone claim, the same mechanism that governs histocompatibility testing for solid organ transplant. TransLabs routes these services correctly and coordinates with cost report preparation where applicable.
Human cell and tissue products are regulated under 21 CFR Part 1271, and tissue banks are generally expected to maintain accreditation with the American Association of Tissue Banks or an equivalent body to support payer relationships. TransLabs verifies tissue product documentation aligns with these regulatory and accreditation expectations before claims are submitted.
Many tissue allografts and skin substitutes are billed under specific HCPCS Q-codes with distinct OPPS pass-through payment status that changes as products move on and off the pass-through list. TransLabs monitors CMS pass-through status changes continuously and updates billing accordingly.
Payers generally expect immunosuppressant trough level testing frequency to align with the patient's time since transplant and clinical stability, tapering as dosing stabilizes. TransLabs validates testing frequency against each patient's clinical course to prevent avoidable medical necessity denials.
Each Medicare Administrative Contractor and commercial payer maintains its own coverage policy for dd-cfDNA and gene expression profiling tests, including minimum days-post-transplant thresholds and organ-specific criteria. TransLabs maintains live coverage databases and validates every claim against the applicable policy.
The CLFS and applicable PLA code pricing govern Medicare payment rates for molecular rejection surveillance and related testing, updating regularly as new codes are introduced. TransLabs monitors these changes and tracks PAMA reporting obligations to ensure accurate, on-time compliance.
Most billing companies have never encountered organ acquisition cost center billing and don’t know it exists, let alone how to route a claim through it correctly. TransLabs was built for laboratory billing exclusively, and our histocompatibility team understands the fee-for-service side and the cost-report side of this specialty.
Join 500+ diagnostic and clinical laboratories, transplant programs, and tissue banks that trust TransLabs, the laboratory billing company built for growth. Start with our complimentary claims audit. Our transplant billing specialists will review your rejection surveillance coding, your immunosuppressant monitoring documentation, and your tissue bank Q-code accuracy to show you exactly what’s recoverable.
Dedicated billing specialist assigned to your program or tissue bank
Complimentary 12-month claims audit across Medicare, Medicaid, and commercial payers
Uncover your top 3 revenue leaks (frequency miscoding, Q-code errors, timing denials)
Custom strategy tailored to your test menu and LIS/billing software
Live in 24 hours with no contracts and no upfront fees
Pay only a percentage of what we collect for you
